Parkinson's disease and related disorders
Conditions
Interventions
DLB group:None
CBS group:None
ET group:None
VPS group:None
iRBD group:None
Sponsors
Beijing Tiantan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients must meet at least one of the following diagnostic criteria: (1) Meet the 2015 Movement Disorder Society (MDS) clinical diagnostic criteria for Parkinson’s disease (PD group); (2) Meet the 2022 MDS diagnostic criteria for Multiple System Atrophy (MSA group); (3) Meet the 2017 MDS diagnostic criteria for Progressive Supranuclear Palsy (PSP group); (4) Meet the 2017 diagnostic criteria for Dementia with Lewy Bodies (DLB group); (5) Meet the 2013 diagnostic criteria for Corticobasal Syndrome (CBS group) proposed by Melissa et al.; (6) Meet the 2011 National Institute on Aging–Alzheimer’s Association (NIA-AA) diagnostic criteria for Alzheimer’s disease (AD group); (7) Meet the 2018 MDS diagnostic criteria for Essential Tremor (ET group); (8) Meet the 2017 diagnostic criteria for Vascular Parkinsonism issued by the Chinese Medical Association (VP group); (9) Diagnosed with idiopathic REM Sleep Behavior Disorder (iRBD group) confirmed by polysomnography; (10) Healthy controls (HC group) matched for age and sex with the PD group, with no history of neurological disorders; 2. Age > 18 years; 3. Written informed consent is obtained.
Exclusion criteria
Exclusion criteria: 1. Presence of other neurological disorders in addition to the inclusion diagnoses; 2. Severe anxiety, depression, or schizophrenia; 3. Serious comorbidities involving the heart, lungs, liver, kidneys, endocrine system, or hematologic system; 4. Conditions that may interfere with clinical assessments, such as aphasia, severe dysarthria, or non-native Chinese speakers; 5. Pregnant or lactating women; 6. Expected poor compliance with study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| neurofilament light chain;glial fibrillary acidic protein;tau and phospho-tau species;a-synuclein and phosphorylated a-synuclein species;amyloid beta;seeding activity of a-synuclein and tau proteins;cell type-specific extracellular vesicles;exosomal microRNA;metabolomics;blood biomarkers; | — |
Secondary
| Measure | Time frame |
|---|---|
| Standardized Uptake Value on PET;Structural and functiona MRI changes;clinical characteristics; | — |
Countries
China
Contacts
Public ContactTao Feng
Center for Movement Disorders, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Outcome results
None listed